OXBDF (Oxford BioMedica) Retained Earnings: $-565.4 Mil (As of Dec. 2025)


OXBDF Oxford BioMedica PLC OXBDF
71 GF Score
Price $7.93
GF Value $6.90
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Retained Earnings?

Oxford BioMedica OXBDF 71 Retained Earnings is $-565.4 Mil as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.90 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oxford BioMedica's retained earnings for the quarter that ended in Dec. 2025 was $-565.4 Mil.

Oxford BioMedica's quarterly retained earnings declined from Dec. 2024 ($-505.1 Mil) to Jun. 2025 ($-571.1 Mil) but then increased from Jun. 2025 ($-571.1 Mil) to Dec. 2025 ($-565.4 Mil).

Oxford BioMedica's annual retained earnings declined from Dec. 2023 ($-446.7 Mil) to Dec. 2024 ($-505.1 Mil) and declined from Dec. 2024 ($-505.1 Mil) to Dec. 2025 ($-565.4 Mil).


Oxford BioMedica  (OTCPK:OXBDF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Oxford BioMedica Retained Earnings Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Retained Earnings Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -220.49 -241.83 -446.73 -505.06 -565.40

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.73 -496.27 -505.06 -571.08 -565.40
OXBDF
71GF Score
Oxford BioMedica PLC OXBDF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-565.4 Mil mean?
Oxford BioMedica (OXBDF) has a Retained Earnings of $-565.4 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Oxford BioMedica and its competitors.
Is Oxford BioMedica's Retained Earnings too high?
Oxford BioMedica's current Retained Earnings is $-565.4 Mil. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Retained Earnings compare to VRTX and REGN?
Oxford BioMedica's Retained Earnings of $-565.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Retained Earnings is $-565.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.90, compared to a current price of $7.93 — trading 14.9% above its estimated fair value. The current Retained Earnings is $-565.4 Mil. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Retained Earnings is $-565.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.93 is trading 14.9% above its estimated GF Value™ of $6.90. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Retained Earnings: $-565.4 Mil
  • GF Value™: $6.90 vs. price of $7.93 (14.9% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for OXBDF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.93
Price
$6.90
GF Value